NRX Pharmaceuticals, Inc. entered into a securities purchase agreement, issuing 3,000,000 shares of Series A Convertible Preferred Stock and one investor warrant for every share, with aggregate proceeds of $1.2 million. The company also filed a Certificate of Designation authorizing up to 12,000,000 shares of Series A Convertible Preferred Stock.